Gilead stock pared its gains Friday after beating first-quarter sales forecasts on the back of its Covid treatment, Veklury.
Gilead (GILD) reports narrower-than-expected loss in the first quarter. Its sales beat estimates on higher HIV, Oncology and Liver Disease sales.
Q1 2024 Gilead Sciences Inc Earnings Call